Decreased diabetes risk over 9 year after 18-month oral l-arginine treatment in middle-aged subjects with impaired glucose tolerance and metabolic syndrome (extension evaluation of l-arginine study)

Autor: Serena Spadoni, Lucilla D. Monti, Pier Marco Piatti, Barbara Fontana, Elena Galluccio, Valentina Villa
Jazyk: angličtina
Rok vydání: 2017
Předmět:
l-Arginine
Blood Glucose
medicine.medical_specialty
Diabetes risk
medicine.medical_treatment
Medicine (miscellaneous)
Administration
Oral
030209 endocrinology & metabolism
Type 2 diabetes
030204 cardiovascular system & hematology
Arginine
Impaired glucose tolerance
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Insulin resistance
Diabetes mellitus
Internal medicine
Surveys and Questionnaires
Glucose Intolerance
medicine
Humans
Insulin
Exercise
Metabolic Syndrome
Nutrition and Dietetics
C-Peptide
business.industry
C-peptide
Insulin secretion
Endothelial Cells
Endothelial function
Original Contribution
Prevention of type 2 diabetes
Middle Aged
medicine.disease
Diet
Oxidative Stress
Endocrinology
Treatment Outcome
chemistry
Diabetes Mellitus
Type 2
Sample Size
Metabolic syndrome
Insulin Resistance
business
Follow-Up Studies
Zdroj: European Journal of Nutrition
ISSN: 1436-6215
1436-6207
Popis: Purpose This study aimed to determine whether l-arginine supplementation lasting for 18 months maintained long-lasting effects on diabetes incidence, insulin secretion and sensitivity, oxidative stress, and endothelial function during 108 months among subjects at high risk of developing type 2 diabetes. Methods One hundred and forty-four middle-aged subjects with impaired glucose tolerance and metabolic syndrome were randomized in 2006 to an l-arginine supplementation (6.4 g orally/day) or placebo therapy lasting 18 months. This period was followed by a 90-month follow-up. The primary outcome was a diagnosis of diabetes during the 108 month study period. Secondary outcomes included changes in insulin secretion (proinsulin/c-peptide ratio), insulin sensitivity (IGI/HOMA-IR), oxidative stress (AOPPs), and vascular function. After the 18 month participation, subjects that were still free of diabetes and willing to continue their participation (104 subjects) were further followed until diabetes diagnosis, with a time span of about 9 years from baseline. Results Although results derived from the 18 month of the intervention study demonstrated no differences in the probability of becoming diabetics, at the end of the study, the cumulative incidence of diabetes was of 40.6% in the l-arginine group and of 57.4% in the placebo group. The adjusted HR for diabetes (l-arginine vs. placebo) was 0.66; 95% CI 0.48, 0.91; p
Databáze: OpenAIRE
Externí odkaz: